• SMYD2 Inhibition Overcomes Chemoresistance in Renal Cell Car

  2026-08-06

  The reference study demonstrates that inhibiting the histone methyltransferase SMYD2 suppresses tumor progression and overcomes multidrug resistance in clear cell renal cell carcinoma (ccRCC) by downregulating microRNA-125b and reducing P-glycoprotein expression. These findings highlight a mechanistic link between epigenetic regulation, microRNA signaling, and chemotherapeutic efficacy, providing new avenues for targeting drug-resistant RCC.

• IgSF6 Deficiency Boosts Macrophage Antibacterial Activity vi

  2026-08-05

  This study uncovers the regulatory role of ER-localized immunoglobulin IgSF6 in intestinal macrophages, demonstrating that IgSF6 deficiency heightens antibacterial function by promoting ER stress and inflammatory signaling. The findings offer new perspectives on immune regulation and potential targets for modulating intestinal homeostasis.

• Dacarbazine in Cancer Research: Protocols and Innovations

  2026-08-05

  Dacarbazine is a cornerstone antineoplastic chemotherapy drug for modeling DNA damage responses in cancer, with distinct workflow nuances and troubleshooting needs. This article distills best practices—including key insights from recent in vitro evaluation research—to help translational teams optimize experimental setups and interpret complex results with confidence.

• Quinolone–Coumarin Hybrids Show Promise Against Toxoplasma g

  2026-08-04

  A recent study evaluated novel quinolone–coumarin hybrids, derived from fluoroquinolones and novobiocin, for their in vitro antiparasitic efficacy against Toxoplasma gondii. These hybrids demonstrated improved selectivity and potency compared to standard treatments, suggesting potential as leads for new anti-Toxoplasma agents with reduced host cell toxicity.

• Gastrodin and AT1 Blockade Regulate RAS–SIRT3 in Astrocyte R

  2026-08-04

  This study reveals that gastrodin modulates the renin-angiotensin system–SIRT3 axis and proinflammatory signaling in reactive astrocytes via microglia activation. It also demonstrates that AT1 receptor inhibition, using azilsartan, directly affects astrocyte phenotype, providing mechanistic insights for neuroinflammation research.

• GM 6001 (Galardin): Reliable Matrix Metalloproteinase Inhibi

  2026-08-03

  This article examines the practical value of GM 6001 (Galardin) Broad Spectrum Matrix Metalloproteinase Inhibitor (SKU A4050) for cell viability, proliferation, and extracellular matrix research. Through scenario-driven Q&A, it addresses reproducibility, assay compatibility, and scientific rigor, highlighting how SKU A4050 from APExBIO delivers consistent results across diverse laboratory workflows.

• Doxorubicin Hydrochloride: Applied Workflows in Cancer and C

  2026-08-03

  Doxorubicin hydrochloride (Adriamycin HCl) remains the benchmark for modeling DNA damage, apoptosis, and cardiotoxicity in preclinical research. This article delivers protocol-driven guidance, troubleshooting strategies, and a translational perspective—empowering scientists to maximize experimental rigor with APExBIO’s validated reagent.

• Translating Berberine Hydrochloride: Mechanistic Leverage fo

  2026-08-02

  This thought-leadership article explores how Berberine Hydrochloride, a natural isoquinoline alkaloid and AMPK activator, is redefining translational research across metabolic and inflammation-related disease models. By integrating mechanistic findings—such as AMPK activation, apoptosis regulation, and NLRP3 inflammasome modulation—with strategic laboratory guidance, the article offers actionable insights for experimental design, highlighting APExBIO’s Berberine Hydrochloride as a benchmark reagent. The discussion bridges recent advances in acute kidney injury research, and provides a visionary outlook on leveraging Berberine for next-generation metabolic and inflammatory studies.

• Dacarbazine in Precision Oncology: Integrating Mechanism wit

  2026-08-01

  Explore the role of Dacarbazine as a leading antineoplastic chemotherapy drug through the lens of modern in vitro assay design and cancer biology. This article uniquely bridges pharmacologic mechanism, quantitative response evaluation, and evidence-based assay optimization for researchers.

• Cycloastragenol Inhibits Osteoclast Activity in Steroid-Indu

  2026-07-31

  This study demonstrates that cycloastragenol significantly prevents bone loss in a rat model of glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) by inhibiting osteoclast activity and downregulating osteoclastogenic genes. The findings provide mechanistic insight into GIONFH pathogenesis and reveal a promising direction for non-surgical hip preservation.

• Pregnenolone Carbonitrile: PXR Agonist for Hepatic Protectio

  2026-07-31

  Pregnenolone Carbonitrile (PCN) is a potent rodent pregnane X receptor agonist central to hepatic detoxification and liver fibrosis studies. This article details its molecular action, evidence from recent studies, and protocol considerations for research workflows.

• Verapamil ((±)-Verapamil): Bridging Hypoxia and Inflammation

  2026-07-30

  This thought-leadership article examines how Verapamil ((±)-Verapamil) is redefining the analysis of hypoxia-induced inflammation, particularly in the context of urothelial cell models. It integrates mechanistic insights from recent literature with practical protocol guidance for translational researchers, highlighting the compound’s unique dual action as a calcium channel blocker and first-generation P-glycoprotein inhibitor. The article contextualizes APExBIO’s Verapamil within the competitive landscape, demonstrates its precise workflow advantages, and articulates a cross-domain vision for advancing inflammation research.

• 3-(1-methylpyrrolidin-2-yl)pyridine (N2703): Precision Modul

  2026-07-30

  Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) enables targeted, high-fidelity modulation of cardiac cellular signaling pathways. This cornerstone article reveals advanced assay strategies and practical implications for biomedical research, providing a fresh perspective beyond existing reviews.

• Unlocking Notch Pathway Precision: DAPT (GSI-IX) in Translat

  2026-07-29

  Explore the mechanistic insight and translational promise of DAPT (GSI-IX), a potent γ-secretase inhibitor, as it empowers next-generation research in Alzheimer's disease, cancer, and regenerative medicine. This thought-leadership piece bridges rigorous biology with actionable strategies for translational scientists, contextualizing recent Notch pathway discoveries and highlighting APExBIO’s DAPT for advanced experimental control.

• Nanoparticle Uptake in Corneal Cells: Impact of Size and Sur

  2026-07-29

  This study systematically examines how nanoparticle size and surface modifications influence their uptake mechanisms by human cornea epithelial cells, using an in vitro model that closely mimics the ocular mucosal environment. Findings reveal that endocytic pathways, especially macropinocytosis and caveolae-mediated endocytosis, are key to optimizing nanoparticle-based drug delivery for ocular therapies.

8594 records 6/573 page Previous Next First page 上5页 678910 下5页 Last page